Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb;104(2):410-414.
doi: 10.1097/TP.0000000000002886.

Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients

Tobias Veit  1 , Dieter Munker  1 , Teresa Kauke  2 , Michael Zoller  3 , Sebastian Michel  4 , Felix Ceelen  1 , Sanziana Schiopu  1 , Jürgen Barton  1 , Paola Arnold  1 , Katrin Milger  1 , Jürgen Behr  1 , Nikolaus Kneidinger  1
Affiliations
Case Reports

Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients

Tobias Veit et al. Transplantation. 2020 Feb.

Abstract

Background: Cytomegalovirus (CMV)-infection remains a major cause of morbidity and mortality after lung transplantation. Treatment with currently available drugs poses treatment difficulties in some patients due to drug resistance or intolerability.

Methods: We report a series of 4 lung transplant recipients with CMV-infection and treatment failure upon standard care due to antiviral drug resistance and treatment-limiting side effects. As rescue therapy letermovir recently approved for the prophylaxis of CMV-infection in patients after hematopoietic stem cell transplantation was initiated. Patients received 480 mg/day for a follow up of 36.1 ± 12.9 weeks. Efficacy and tolerability were assessed retrospectively.

Results: Mild nausea, vomiting, and diarrhea were the only side effects of letermovir reported by a single patient. A small adjustment of the tacrolimus dose was mandatory upon treatment initiation with letermovir. CMV viral load could be decreased and cleared subsequently in all patients. CMV clearance was observed after 17.7 ± 12.6 weeks despite lack of CMV-immunity.

Conclusions: CMV-infection and -disease were successfully managed with letermovir. Letermovir was well tolerated and effective in treating CMV-infections in lung transplant recipients failing on currently available antiviral agents.

PubMed Disclaimer

References

    1. Zamora MR. Cytomegalovirus and lung transplantation.Am J Transplant200441219–1226
    1. Kurihara C, Fernandez R, Safaeinili N, et al. Long-term impact of cytomegalovirus serologic status on lung transplantation in the United States.Ann Thorac Surg20191071046–1052
    1. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation.Drugs201070965–981
    1. Kneidinger N, Giessen C, von Wulffen W, et al. Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.Int J Infect Dis201428140–142
    1. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.J Clin Virol200635474–477

Publication types